Concept Architecture
Concept
Theoretically, Extended Cost-Effectiveness Analysis (ECEA) is an extension of conventional cost-effectiveness analysis that evaluates healthcare interventions by jointly assessing health gains, financial risk protection and the distribution of benefits across population groups. It is grounded in welfare economics, health economics and equity analysis, recognising that healthcare policies may generate value beyond improvements in health by reducing catastrophic health expenditure and improving equity. ECEA was developed primarily to inform priority setting in low- and middle-income countries where financial protection is a major policy objective.
Mathematically, Extended Cost-Effectiveness Analysis expands the conventional cost-effectiveness framework by estimating multiple outcome measures simultaneously, including health outcomes, out-of-pocket expenditure averted, cases of catastrophic health expenditure prevented and the distribution of these outcomes across socioeconomic groups. Rather than producing a single summary statistic, ECEA estimates several expected outcomes that collectively inform resource allocation decisions.
In practice, Extended Cost-Effectiveness Analysis is implemented using decision-analytic models that combine epidemiological, clinical, utilisation, cost and household expenditure data. Analysts estimate health gains, healthcare costs, financial risk protection and equity impacts for each intervention, frequently stratifying results by income quintile or other population subgroups. ECEA is widely applied in evaluations of universal health coverage policies, vaccination programmes and publicly financed healthcare interventions.
Purpose
Used to evaluate healthcare interventions by simultaneously assessing health outcomes, financial risk protection and equity impacts, thereby informing resource allocation decisions that consider both efficiency and fairness.
Mathematical Formulae
Primary Formula
There is no universally recognised canonical mathematical formula.
Supporting Formulae
Health outcomes are commonly estimated as:
E(H) = ????� p?H?
Expected financial protection may be expressed as:
E(F) = ????� p?F?
where:
- E(H) = expected health outcome
- E(F) = expected financial protection outcome
- p? = probability or population weight
- H? = health outcome
- F? = financial protection outcome
Related Mathematical Methods
- Cost-effectiveness analysis
- Distributional cost-effectiveness analysis
- Decision-analytic modelling
- Probabilistic sensitivity analysis
- Equity analysis
- Catastrophic health expenditure modelling
- Benefit incidence analysis
Example
A national childhood vaccination programme is evaluated using Extended Cost-Effectiveness Analysis.
The programme is estimated to:
- Prevent 4,800 disability-adjusted life years (DALYs).
- Prevent 1,350 cases of catastrophic health expenditure.
- Reduce household out-of-pocket expenditure by �2.4 million.
- Deliver 62% of total financial protection benefits to the lowest two income quintiles.
Rather than reporting only an incremental cost-effectiveness ratio, the analysis demonstrates both health improvement and enhanced financial protection while identifying how benefits are distributed across socioeconomic groups.
Excel Implementation
| Function | Example Formula | Health Economics Application |
|---|---|---|
| SUMPRODUCT | =SUMPRODUCT(B2:B11,C2:C11) | Calculates expected health or financial outcomes using population weights. |
| SUM | =SUM(D2:D11) | Calculates total costs or financial protection benefits. |
| IF | =IF(E2>0,""Protected"",""Not Protected"") | Classifies households experiencing catastrophic expenditure. |
| PERCENTILE | =PERCENTILE.INC(B2:B100,0.2) | Defines income quintiles for equity analysis. |
| PivotTable | Dataset Summary | Summarises health and financial outcomes by socioeconomic group. |
VBA (Optional)
Automate Extended Cost-Effectiveness Analysis by calculating health outcomes, financial protection measures and equity distributions across multiple intervention scenarios.
Sources
- Verguet S, Laxminarayan R, Jamison DT. Universal Public Finance of Tuberculosis Treatment in India: An Extended Cost-Effectiveness Analysis. Health Economics. 2015.
- Verguet S, Kim JJ, Jamison DT. Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. Pharmacoeconomics. 2016.
- Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 4th ed. Oxford University Press; 2015.
- Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford University Press; 2006.
- NICE. Health Technology Evaluation Manual. Latest edition.
Related Concepts (2)
Library
Publications
1
Methods for the Economic Evaluation of Health Care Programmes — Drummond, Sculpher, Claxton, Stoddart & Torrance, 4th Edition ed., 2015 (Oxford University Press)
The standard international reference text for economic evaluation methods in health care, covering cost-effectiveness, cost-utility and cost-benefit analysis, measurement of costs and outcomes, evidence synthesis, and the characterisation of uncertainty.
BookView source →
Frequently Asked Questions (6)
What is extended cost-effectiveness analysis?
A form of economic evaluation that extends standard cost-effectiveness analysis by incorporating financial risk protection and the distribution of costs and benefits by income.
Source: Verguet, Laxminarayan & Jamison 2015
What does extended cost-effectiveness analysis add?
It reports three consequences of a policy rather than one. Health gains are disaggregated by income group rather than aggregated across the population. Financial risk protection is estimated, meaning the out-of-pocket expenditure averted and the cases of catastrophic or impoverishing health spending prevented. And the distribution of the public spending required is examined, showing which groups the subsidy reaches. The method was developed for settings where a large share of health spending is paid directly by households, so that a policy's value lies as much in the financial protection it provides as in the health it produces.
Source: Verguet, Laxminarayan & Jamison 2015
Why does extended cost-effectiveness analysis measure financial risk protection?
Because in systems with substantial out-of-pocket payment, illness imposes two distinct harms: the loss of health and the loss of financial security. A household facing a large medical bill may forgo treatment, sell assets or fall into poverty, and none of that appears in a conventional analysis measuring health outcomes alone. Publicly funding a treatment therefore delivers a benefit beyond the health gained, and a method that ignores it understates the value of coverage expansion in exactly the settings where coverage matters most. Health and financial protection are reported side by side rather than combined, since converting one into the other would require a weighting the method deliberately leaves to the decision maker.
Source: Verguet, Laxminarayan & Jamison 2015
What does extended cost-effectiveness analysis require?
Evidence on how disease incidence, treatment uptake and out-of-pocket payment vary by income group, which household survey data can supply in many settings. It requires an estimate of how a public subsidy would be distributed, which depends on who currently receives care and who would newly receive it. And it requires a threshold or criterion for financial protection, since averting catastrophic spending has no natural unit comparable to a health gain, so the results are normally reported alongside rather than combined. Where household survey data are unavailable, the distributional components have to be assumed, at which point the analysis reports a scenario rather than an estimate.
Source: Drummond et al. 2015
Where is extended cost-effectiveness analysis used?
It has been applied mainly to policy questions in low and middle income countries, including which services to include in a publicly financed benefits package, whether to subsidise particular treatments, and how tobacco or other taxation affects health and household finances across income groups. Its relevance extends to any system where households face substantial charges, and it is less informative where care is free at the point of use and the financial protection component is small. It has also been applied to questions about universal coverage design, where the interest lies in who benefits from a subsidy as much as in how much health it produces.
Source: Verguet, Laxminarayan & Jamison 2015
What are the limitations of extended cost-effectiveness analysis?
It produces several results rather than one, so it informs a judgement rather than delivering a ranking, and combining health gain with financial protection requires a weighting the method does not supply. The distributional estimates depend heavily on assumptions about who takes up a newly subsidised service, which is difficult to predict. And the data requirements exceed what is available in many of the settings where the method would be most useful. The results are also more difficult to summarise for a decision maker than a single ratio, which limits uptake despite the additional information they carry.
Source: healtheconomics.wiki
Trust Record
Verified by Dr Darrin Baines
British health economist
Professional identity: darrinbaines.org
Verification date: 6 Aug 2025
Content version: 1.0.0
Canonical Identity
- Term code
- HE-EE-CEA-028
Stable URI · Machine-readable · Resolvable · CC BY 4.0